A pharmaceutical composition comprising: (a) (i) an amount of a 5-HT7 receptor antagonist, and (ii) an amount of citalopram or a pharmaceutically acceptable salt thereof, said amounts together providing an effective combined amount; and (b) a pharmaceutically acceptable excipient; wherein said 5-HT7 receptor antagonist is selected from the group consisting of: 1-Benzyl-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; -3-[2-[2-(4-Methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulfonyl]phenol; -3,N-Dimethyl-N-[1-methyl-3-(4-methytpiperidin-1-yl)propyl]benzene sulfonamide; R-(+)-1-(toluene-3-sulfonyl)-2-[2-(4-methylpiperidin-1-yl)ethyl]-pyrrolidine; LY-215840; 2a-[4-4-phenyl-1,2,3,6-tetrahydropyridyl])-2a,3,4,5-tetrahydrobenzo[c,d]-indol-2- -one; Ensaculin; S 23751; Zotepine; BTS 79018; and pharmaceutically acceptable salts thereof, for use in a method of treating a serotonin mediated disease or condition selected from a cognitive disorder, a psychiatric disorder, a sleep disorder, a vascular disorder, a gastrointestinal disorder, urinary incontinence, aberrant hormone secretion, a metabolic disorder, septic shock, a renal disorder, an inflammatory disorder, an ocular disorder, depression, anxiety, generalized anxiety disorder, schizophrenia, a bipolar disorder, a psychotic disorder, obsessive-compulsive disorder, a mood disorder, a stress-related disorder, post-traumatic stress, learning dysfunction, memory dysfunction, migraine, a disorder associated with nociception, pain, an arousal disorder, a vigilance disorder, a disorder associated with aberrant sensory perception, a disorder associated with aberrant motor activity, a disorder associated aberrant thermoregulation, sexual dysfunction, centrally mediated hypotension, alcohol abuse, drug abuse, an addictive disorder, a metabolic disorder, hormonal imbalances, an eating disorder, obesity, insomnia, disturbed sleep, narcolepsy, narcolepsy with associated cataplexy, cataplexy, sleep/wake disturbances, idiopathic somnolence, excessive daytime sleepiness, a circadian rhythm disorder, fatigue, lethargy, jet lag, a cardiovascular disorder, cardiovascular shock, arrhythmia, hypotension, ischemia, stroke, a gastric motility disorder, diarrhea, spastic colon, an irritable bowel disorder, glaucoma, optic neuritis, diabetic retinopathy, retinal edema, or age-related macular degeneration. (a) (i) an amount of a 5-HT7 receptor antagonist, and (ii) an amount of citalopram or a pharmaceutically acceptable salt thereof, said amounts together providing an effective combined amount; and (b) a pharmaceutically acceptable excipient; 1-Benzyl-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; -3-[2-[2-(4-Methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulfonyl]phenol; -3,N-Dimethyl-N-[1-methyl-3-(4-methytpiperidin-1-yl)propyl]benzene sulfonamide; R-(+)-1-(toluene-3-sulfonyl)-2-[2-(4-methylpiperidin-1-yl)ethyl]-pyrrolidine; LY-215840; 2a-[4-4-phenyl-1,2,3,6-tetrahydropyridyl])-2a,3,4,5-tetrahydrobenzo[c,d]-indol-2- -one; Ensaculin; S 23751; Zotepine; BTS 79018; and pharmaceutically acceptable salts thereof, for use in a method of treating a serotonin mediated disease or condition selected from a cognitive disorder, a psychiatric disorder, a sleep disorder, a vascular disorder, a gastrointestinal disorder, urinary incontinence, aberrant hormone secretion, a metabolic disorder, septic shock, a renal disorder, an inflammatory disorder, an ocular disorder, depression, anxiety, generalized anxiety disorder, schizophrenia, a bipolar disorder, a psychotic disorder, obsessive-compulsive disorder, a mood disorder, a stress-related disorder, post-traumatic stress, learning dysfunction, memory dysfunction, migraine, a disorder associated with nociception, pain, an arousal disorder, a vigilance disorder, a disorder associated with aberrant sensory perception, a disorder associated with aberrant motor activity, a disorder associated aberrant thermoregulation, sexual dysfunction, centrally mediated hypotension, alcohol abuse, drug abuse, an addictive disorder, a metabolic disorder, hormonal imbalances, an eating disorder, obesity, insomnia, disturbed sleep, narcolepsy, narcolepsy with associated cataplexy, cataplexy, sleep/wake disturbances, idiopathic somnolence, excessive daytime sleepiness, a circadian rhythm disorder, fatigue, lethargy, jet lag, a cardiovascular disorder, cardiovascular shock, arrhythmia, hypotension, ischemia, stroke, a gastric motility disorder, diarrhea, spastic colon, an irritable bowel disorder, glaucoma, optic neuritis, diabetic retinopathy, retinal edema, or age-related macular degeneration.